03:56:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2022-01-26 Bokslutskommuniké 2021
2021-07-14 Kvartalsrapport 2021-Q2
2021-06-30 Årsstämma 2021
2021-05-27 Ordinarie utdelning NATTO 0.00 NOK
2021-02-17 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-07-15 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning NATTO 0.00 NOK
2020-06-19 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-19 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NATTO 0.00 NOK
2019-05-29 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NATTO 0.00 NOK
2018-05-30 Årsstämma 2018
2018-02-08 Bokslutskommuniké 2017
2017-11-24 Extra Bolagsstämma 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Ordinarie utdelning NATTO 0.00 NOK
2017-05-15 Kvartalsrapport 2017-Q1
2017-05-15 Kapitalmarknadsdag 2017
2017-05-15 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-20 Kvartalsrapport 2016-Q1
2016-05-20 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-27 Kvartalsrapport 2014-Q1
2014-02-17 Bokslutskommuniké 2013
2013-11-26 Kvartalsrapport 2013-Q3
2013-08-27 Kvartalsrapport 2013-Q2
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-16 Kvartalsrapport 2012-Q1
2012-02-28 Bokslutskommuniké 2011
2012-02-13 Extra Bolagsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-31 Extra Bolagsstämma 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-19 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2021-03-29 17:27:07

Oslo, Norway (29 March 2021) -

Reference is made to the offer document dated 8 March 2021 (the "Offer Document") for the recommended voluntary offer by Compagnie des Levures Lesaffre (the "Offeror") to acquire all outstanding shares in NattoPharma ASA ("NattoPharma" or the "Company") against a consideration in cash of NOK 35 per share (the "Offer"), and further reference is made to the stock exchange announcement dated 29 March 2021 in which the Offeror announced that the voluntary offer is completed.

The Offeror had obtained pre-commitments from Shareholders representing approximately 65.10% (on a Fully Diluted basis, excluding treasury shares) of the Shares to tender their Shares pursuant to the Offer. The pre-commitments included 1,655,122 shares by primary insiders of the Company and 7,855,611 shares by close associates of primary insiders of the Company (as listed below):
  • Bohan & Co AS as close associate to Chairman of the Board sold 1,298,455 shares in this transaction. Following this transaction Bohan & Co AS will not hold any shares in NattoPharma.
  • TG Montgomery AS as close associate to Chairman of the Board Frode Bohan and deputy Board Member Kim Øien sold 2,121,482 shares in this transaction. Following this transaction TG Montgomery AS will not hold any shares in NattoPharma.
  • Patrycja Ratunsinska as close associatie to Chairman of the Board sold 350,000 shares in this transaction. Following this transaction Patrycja Ratunsinska will not hold any shares in NattoPharma.
  • Primary insider and Chairman of the Board Frode Bohan sold 100,000 shares in this transaction. Following this transaction Frode Bohan will not hold any shares in NattoPharma.
  • Nicole Invest AS as close associate to deputy Board Member Kim Øien sold 200,000 shares in this transaction. Following this transaction Nicoline Invest AS will not hold any shares in NattoPharma.
  • Grethe Eggesbøe Thorsheim as close associate to Board Member Sjur Thorsheim sold 21,000 in this transaction. Following this transaction Grethe Eggesbøe Thorsheim will not hold any shares in NattoPharma.
  • Pro AS as close associate to Board Member Sjur Thorsheim sold 2,861,310 shares in this transaction. Following this transaction Pro AS will not hold any shares in NattoPharma.
  • Primary insider and Board Member Sjur Thorsheim sold 100,000 shares in this transaction. Following this transaction Sjur Thorsheim will not hold any shares in NattoPharma.
  • Life Science Sweden AB as close associate to Board Member Stefan Hallden sold 647,654 shares in this transaction. Following this transaction Life Science Sweden AB will not hold any shares in NattoPharma.
  • Primary insider and Board Member Stefan Hallden sold 310,800 shares in this transaction. Following this transaction Stefan Hallden will not hold any shares in NattoPharma.
  • Tontine AB as close associate to Board Member Stefan Hallden sold 81,210 shares in this transaction. Following this transaction Tontine AB will not hold any shares in NattoPharma.
  • Primary insider and Board Member Annette Elmqvist sold 150,000 shares in this transaction. Following this transaction Annette Elmqvist will not hold any shares in NattoPharma.
  • Primary insider and Board Member Katarzyna Maresz sold 125,000 shares in this transaction. Following this transaction Katarzyna Maresz will not hold any shares in NattoPharma.
  • Cinco Invest AS as close associate to Chief Executive Officer Kjetil Ramsøy sold 300,000 shares in this transaction. Following this transaction Cinco Invest AS will not hold any shares in NattoPharma.
  • Primary insider and Chief Executive Officer Kjetil Ramsøy sold 275,100 shares in this transaction. Following this transaction Kjetil Ramsøy will not hold any shares in NattoPharma.
  • Primary insider and Chief Financial Officer Robert Schrama sold 33,000 shares in this transaction. Following this transaction Robert Schrama will not hold any shares in NattoPharma.
  • Primary insider Elise Kaiser sold 40,000 shares in this transaction. Following this transaction Elise Kaiser will not hold any shares in NattoPharma.
  • Primary insider Laura Bakker sold 81,000 shares in this transaction. Following this transaction Laura Bakker will not hold any shares in NattoPharma.
  • Primary insider Andrew Green sold 20,000 shares in this transaction. Following this transaction Andrew Green will not hold any shares in NattoPharma.
  • Primary insider Randall Eric Anderson sold 191,750 shares in this transaction. Following this transaction Randall Eric Anderson will not hold any shares in NattoPharma.
  • Primary insider Rudi De Man sold 86,000 shares in this transaction. Following this transaction Rudi De Man will not hold any shares in NattoPharma.
  • RDM Health & Nutrition BVBA as close associate to Primary Insider Rudi De Man sold 60,500 shares. Following this transaction RDM Health & Nutrition BVBA will not hold any shares in NattoPharma.
  • Primary insider William Sommer sold 142,472 shares in this transaction. Following this transaction William Sommer will not hold any shares in NattoPharma.

Please refer to the attached notifications of trading for further details.

***

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities